Combination of Osimertinib with Concurrent Chemotherapy and Hormonal Therapy for Synchronous NSCLC, Hormone Receptor-Positive Breast Cancer, and Triple-Negative Breast Cancer: Case Report

Patients presenting with multiple primary malignancies remain a growing challenge for physicians due to a lack of data for generalizable guidelines. Identification of driver mutations in carcinogenesis leads to the development of targeted treatment of many different cancer types, but its combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Changsu L., Moria, Feras, Saleh, Ramy R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601812/
https://www.ncbi.nlm.nih.gov/pubmed/37900833
http://dx.doi.org/10.1159/000533783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601812/
https://www.ncbi.nlm.nih.gov/pubmed/37900833
http://dx.doi.org/10.1159/000533783

Ejemplares similares